Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:80878 |
Name | IDH-wildtype glioblastoma |
Definition | A glioblastoma that is characterized by high cellularity, high mitotic activity, necrosis or microvascular proliferation and that lacks mutations in IDH genes. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer cell type cancer high grade glioma malignant astrocytoma glioblastoma IDH-wildtype glioblastoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
BRAF V600E | Vemurafenib | IDH-wildtype glioblastoma | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03158389 | Phase Ib/II | Vismodegib Alectinib Idasanutlin Temsirolimus Atezolizumab Palbociclib APG101 | NCT Neuro Master Match - N²M² (NOA-20) (N²M²) | Recruiting | DEU | 0 |
NCT04910022 | Phase Ib/II | NMS-03305293 + Temozolomide Lomustine | Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma | Recruiting | USA | ITA | 2 |
NCT04945148 | Phase II | Metformin + Temozolomide | Oxidative Phosphorylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy Temozolomide (OPTIMUM) | Not yet recruiting | ITA | FRA | 0 |
NCT05256290 | Phase I | BDTX-1535 | Study of BDTX-1535, in Participants With Glioblastoma or Non-Small Cell Lung Cancer | Recruiting | USA | 1 |
NCT05267106 | Phase II | Pemigatinib | Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209) | Recruiting | USA | ITA | FRA | ESP | DEU | 4 |
NCT05432375 | Phase I | Tinostamustine | Study of Tinostamustine for Adjuvant Treatment of Glioblastoma | Recruiting | ESP | 1 |
NCT05463848 | Phase II | Olaparib + Pembrolizumab + Temozolomide Pembrolizumab | Surgical Pembro +/- Olaparib w TMZ for rGBM | Recruiting | USA | 0 |
NCT05465954 | Phase II | NT-I7 + Pembrolizumab | Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma | Not yet recruiting | USA | 0 |